Immunotherapy in Multiple Myeloma: Emerging Strategies

Immunotherapy in Multiple Myeloma: Emerging Strategies

View Activity

Activity Features


Downloadable Slides

Interactive Presentation

Activity Overview

Expert faculty presentations with downloadable slides from our satellite symposium at the 2017 International Myeloma Workshop cover the rationale for immunologic therapies in multiple myeloma and how they benefit patients, as well as clinical trial results and how to incorporate those data into the daily care of your patients with multiple myeloma.


Immunotherapy in multiple myeloma: Where we are now
Darrell White, MD, MSc, FRCPC, FACP

Examining strategies to tailor immunotherapy to the patient with multiple myeloma
Jeffrey Zonder, MD

The biology behind immunotherapy in multiple myeloma and its implications for the future
Alexander Lesokhin, MD 

prIME Points™
Alexander Lesokhin, MD


  • Alexander Lesokhin, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Darrell White, MD, MSc FRCPC, FACPDalhousie University
    Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia, Canada
  • Jeffrey Zonder, MDKarmanos Cancer Institute
    Detroit, Michigan, United States

Target Audience

This educational activity is specifically designed to meet the needs of medical oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Describe current novel immunotherapy options in relapsed/refractory (R/R) multiple myeloma
  • Tailor/individualize immunotherapy in multiple myeloma to disease burden and biology
  • Explain the biology behind immunotherapy in R/R multiple myeloma and the future of immunotherapeutic approaches
View Activity


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.


prIME Oncology designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME and Disclosure Information


This educational activity is supported by a grant from Bristol-Myers Squibb.

Activity Date

March 31, 2017

March 31, 2018